Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

被引：180

作者：

Petrov, Kimberly G. ^{[1
]}

Zhang, Yue-Mei ^{[1
]}

Carter, Malcolm ^{[1
]}

Cockerill, G. Stuart ^{[1
]}

Dickerson, Scott ^{[1
]}

Gauthier, Cassandra A. ^{[1
]}

Guo, Yu ^{[1
]}

Mook, Robert A., Jr. ^{[1
]}

Rusnak, David W. ^{[1
]}

Walker, Ann L. ^{[1
]}

Wood, Edgar R. ^{[1
]}

Lackey, Karen E. ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Res Triangle Pk, NC USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 17期

关键词：

ErbB-1 tyrosine kinase inhibitors; ErbB-2 tyrosine kinase inhibitors; EGFR kinase inhibitors; quinazoline; lapatinib;

D O I：

10.1016/j.bmcl.2006.05.090

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino provided the best enzyme potency and cellular selectivity. Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy. The discovery of lapatinib emerged from this work. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：4686 / 4691

页数：6

共 50 条

[21] The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation
Kim, H
Chan, R
Dankort, DL
Zuo, DM
Najoukas, M
Park, M
Muller, WJ
ONCOGENE, 2005, 24 (51) : 7599 - 7607
[22] The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation
Harold Kim
Richard Chan
David L Dankort
Dongmei Zuo
Monica Najoukas
Morag Park
William J Muller
Oncogene, 2005, 24 : 7599 - 7607
[23] Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and ErbB-2 Receptors
Oh, Yoon Sin
Shin, Seungjin
Lee, Youn-Jung
Kim, Eung Hwi
Jun, Hee-Sook
PLOS ONE, 2011, 6 (08):
[24] HETERODIMERIZATION OF THE ERBB-1 AND ERBB-2 RECEPTORS IN HUMAN BREAST-CARCINOMA CELLS - A MECHANISM FOR RECEPTOR TRANSREGULATION
GOLDMAN, R
BENLEVY, R
PELES, E
YARDEN, Y
BIOCHEMISTRY, 1990, 29 (50) : 11024 - 11028
[25] The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer
Rusnak, DW
Affleck, K
Cockerill, SG
Stubberfield, C
Harris, R
Page, M
Smith, KJ
Guntrip, SB
Carter, MC
Shaw, RJ
Jowett, A
Stables, J
Topley, P
Wood, ER
Brignola, PS
Kadwell, SH
Reep, BR
Mullin, RJ
Alligood, KJ
Keith, BR
Crosby, RM
Murray, DM
Knight, WB
Gilmer, TM
Lackey, K
CANCER RESEARCH, 2001, 61 (19) : 7196 - 7203
[26] Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer
Martinello, Rossella
Milani, Andrea
Geuna, Elena
Zucchini, Giorgia
Aversa, Caterina
Nuzzo, Annamaria
Montemurro, Filippo
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 393 - 403
[27] Competitive-differential polymerase chain reaction for gene dosage estimation of erbB-1 (egfr), erbB-2, and erbB-3 oncogenes
Roetger, A
Brandt, B
Barnekow, A
DNA AND CELL BIOLOGY, 1997, 16 (04) : 443 - 448
[28] The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development
Chan, R
Hardy, WR
Laing, MA
Hardy, SE
Muller, WJ
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (04) : 1073 - 1078
[29] A Comparative QSAR Analysis of Quinazoline Analogues as Tyrosine Kinase (erbB-2) Inhibitors
Noolvi, Malleshappa N.
Patel, Harun M.
Bhardwaj, Varun
MEDICINAL CHEMISTRY, 2011, 7 (03) : 200 - 212
[30] Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer
Singla, Smit
Pippin, James A.
Drebin, Jeffrey A.
ONCOLOGY REPORTS, 2012, 28 (06) : 2211 - 2216

← 1 2 3 4 5 →